title: [Immunological characteristics in the therapy of atopic dermatitis in children with polycomponent vaccine Immunovac BN-4].
abstract: IgE-mediated reactions linked with the polarization of the immune process towards, mainly, the activation of Th2 lymphocytes which synthesized interleukins, responsible for switching over B lymphocytes to the production of IgE, were found to be the most important mechanism of the pathogenesis of atopic dermatitis (AD). The use of immunomodulating preparations, capable of changing unbalance in the system of Th1/Th2 cells, is one of promising approaches to the complex therapy of AD. Poly-component vaccine Immunovac BN-4 was included into the complex therapy of AD in children, The dynamics of immunological characteristics was studied for the period of 6 months after the end of the course of therapy. A considerable increase in the absolute and relative amount of lymphocytes with markers CD3, CD4, CD16, CD21, CD25, a rise in the levels of IgA, IgG and a decrease in the level of total IgE in the blood serum were established. The inclusion of the polycomponent vaccine into the complex therapy of AD may be recommended.
authors.forename: O E
authors.initials: OE
authors.lastname: Nemykina
authors.forename: N B
authors.initials: NB
authors.lastname: Egorova
authors.forename: B V
authors.initials: BV
authors.lastname: Shcherbakova
authors.forename: E A
authors.initials: EA
authors.lastname: Kurbatova
authors.forename: I B
authors.initials: IB
authors.lastname: Semenova
authors.forename: V N
authors.initials: VN
authors.lastname: Efremova
authors.forename: I M
authors.initials: IM
authors.lastname: Gruber
authors.forename: B F
authors.initials: BF
authors.lastname: Semenov
mesh_terms: D000281:Administration, Intranasal; D000284:Administration, Oral; D000293:Adolescent; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D017252:CD3 Complex / Q000032:analysis; D015704:CD4 Antigens / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D003876:Dermatitis, Atopic / Q000097:blood / Q000628:therapy*; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007073:Immunoglobulin E / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D008214:Lymphocytes / Q000097:blood / Q000276:immunology; D017464:Receptors, Complement 3d / Q000032:analysis; D017452:Receptors, IgG / Q000032:analysis; D015375:Receptors, Interleukin-2 / Q000032:analysis; D013997:Time Factors; D017778:Vaccines, Combined / Q000627:therapeutic use*
chemical_list: D001428:Bacterial Vaccines; D017252:CD3 Complex; D015704:CD4 Antigens; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D017464:Receptors, Complement 3d; D017452:Receptors, IgG; D015375:Receptors, Interleukin-2; C088865:VP-4 vaccine; D017778:Vaccines, Combined; D007073:Immunoglobulin E